Personalized medicine for childhood arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or younger.
- You have been diagnosed with juvenile idiopathic arthritis (JIA) or have symptoms that make doctors suspect JIA.
- Depending on the group, you may need to be about to start a new biologic, switch biologics, or stop them because your disease is quiet.
- For the extreme group, you have hard-to-treat arthritis with possible genetic cause.
- You have not had joint injections in the last 4 weeks (for some groups).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how best to estimate a child’s likely symptoms and treatment response in the first phase after a new JIA diagnosis. It may help families and clinicians make clearer, more personalized decisions about care.
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This study looks at children with arthritis to better understand their condition using clinical exams, lab tests, and ultrasounds. It may help doctors learn more about different types of juvenile arthritis.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This trial tests whether a special diet can help children and teens with juvenile arthritis. If you join, you will follow the diet and provide stool samples so the researchers can see how it affects your gut and arthritis.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.